Case todayBrokenAnalyst downgrade · Oct 27, 2026The case · holding · Nov 17, 2026Own MRNA if mRNA becomes a repeatable multi-product engine, but the stock fails if COVID-era cash is consumed before non-COVID products scale.5 conditions5 holdingNext resultsFeb 12, 2027Projected from its filing dates

MRNA at a glance

The past year

Chart

+769.1% $215.27, close Nov 16

From the highest close
−20.0%
Vs the 200-day average
+121.3%
Nov 14, 2025Daily close, ModernaNov 16, 2026

Short interest

History

33.2M shares

Of shares outstanding
8.20%
Since the last report
+1.8%
Days to cover
1.8 days
Settled
Oct 30, 2026

Insider buying, 7 days

Filings

None filed this week

Form 4s filed
Nov 10 – Nov 16

Top investors

Funds

1 of 37 funds hold it

Ray Dalio
0.0%
Latest 13F filings
0 added · 1 cut

Understand the Business

Why the Stock Moved

Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.

MRNA price history

Latest price$215.27Today−$8.10 (-3.63%)
MRNA -4.59%S&P 500 -3.79%Since first plotted close
4 hours

Loading recent earnings…

Investment thesis

What must happen next

5 MATERIAL PROPOSITIONS
  • Moderna’s mRNA platform must produce commercially adopted products beyond the pandemic franchise, proving that shared mRNA design and manufacturing know-how can be reused across diseases rather than being a one-product success.HoldingMateriality: High

    The company describes itself as advancing a technology platform to reimagine how medicines are made. If the platform is repeatable, today’s losses can be investment in future franchises; if not, the pipeline spend destroys the COVID windfall.

    Watch: Late-stage non-COVID mRNA programs fail efficacy or safety endpoints, showing the platform does not generalize.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    The company describes itself as advancing a technology platform to reimagine how medicines are made.

    Open source ↗
  • Seasonal respiratory vaccines must become a durable, priced commercial channel for Moderna, not merely a lower-volume replacement for pandemic purchasing.HoldingMateriality: High

    FY2025 annual GAAP gross profit was $1.076 billion on $1.944 billion of revenue, indicating positive product economics remain. Revenue that returns at poor price, mix, or utilization will not rebuild the earnings power implied by the platform story.

    Watch: CDC/ACIP or international advisory bodies narrow respiratory vaccine eligibility, reducing the recurring addressable market.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    FY2025 annual GAAP gross profit was $1.076 billion on $1.944 billion of revenue, indicating positive product economics remain.

    Open source ↗
  • Moderna has to make its R&D, manufacturing, and commercial infrastructure flexible enough for post-pandemic demand; otherwise the platform’s scientific optionality will be overwhelmed by fixed operating costs.HoldingMateriality: Medium

    FY2025 annual GAAP operating loss was $3.074 billion, improved from a $4.239 billion loss in FY2023. A smaller but high-potential product base can still create value if losses narrow; persistent fixed-cost drag would force the company to cut the pipeline or raise capital.

    Watch: Large Phase 3 programs require sustained spending before commercial proof arrives.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    FY2025 annual GAAP operating loss was $3.074 billion, improved from a $4.239 billion loss in FY2023.

    Open source ↗
  • Management must pace pipeline investment so Moderna reaches value-inflecting approvals or partnerships before operating cash burn forces dilutive financing.HoldingMateriality: Medium

    FY2025 annual GAAP operating cash flow was negative $1.873 billion, better than negative $3.004 billion in FY2024 and negative $3.118 billion in FY2023. Cash runway determines whether shareholders own the pipeline upside or fund it through dilution after the stock has already absorbed the revenue cliff.

    Watch: Clinical failures force Moderna to fund additional large trials without partner support.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    FY2025 annual GAAP operating cash flow was negative $1.873 billion, better than negative $3.004 billion in FY2024 and negative $3.118.

    Open source ↗
  • The platform advantage depends on retaining specialized mRNA, clinical, regulatory, and manufacturing talent that can reuse knowledge across programs; excessive cuts or attrition would slow pipeline conversion.HoldingMateriality: Medium

    Moderna reported approximately 4,700 full-time employees in 18 countries as of December 31, 2025. If the human-capital base is preserved, Moderna can compound learning across programs; if it is hollowed out, cost cuts may improve near-term losses while impairing the core asset.

    Watch: Key scientists, manufacturing leaders, or regulatory executives leave for BioNTech, large pharma, or other biotech competitors.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Moderna reported approximately 4,700 full-time employees in 18 countries as of December 31, 2025.

    Open source ↗
Full investment case & evidence

Loading the original research archive…

Original research

Moderna’s mRNA platform must produce commercially adopted products beyond the pandemic franchise, proving that shared mRNA design and manufacturing know-how can be reused across diseases rather than being a one-product success. If the platform is repeatable, today’s losses can be investment in future franchises; if not, the pipeline spend destroys the COVID windfall.

Seasonal respiratory vaccines must become a durable, priced commercial channel for Moderna, not merely a lower-volume replacement for pandemic purchasing. Revenue that returns at poor price, mix, or utilization will not rebuild the earnings power implied by the platform story.

Moderna has to make its R&D, manufacturing, and commercial infrastructure flexible enough for post-pandemic demand; otherwise the platform’s scientific optionality will be overwhelmed by fixed operating costs. A smaller but high-potential product base can still create value if losses narrow; persistent fixed-cost drag would force the company to cut the pipeline or raise capital.

Management must pace pipeline investment so Moderna reaches value-inflecting approvals or partnerships before operating cash burn forces dilutive financing. Cash runway determines whether shareholders own the pipeline upside or fund it through dilution after the stock has already absorbed the revenue cliff.

The platform advantage depends on retaining specialized mRNA, clinical, regulatory, and manufacturing talent that can reuse knowledge across programs; excessive cuts or attrition would slow pipeline conversion. If the human-capital base is preserved, Moderna can compound learning across programs; if it is hollowed out, cost cuts may improve near-term losses while impairing the core asset.

All standing thesis claims
Original report summary

mRNA becomes a repeatable multi-product engine, but the stock fails if COVID-era cash is consumed before non-COVID products scale.

Evidence assessed Nov 17, 2026. Expand each conclusion for its evidence and what would change it. Thesis evidence—not a buy or sell recommendation.

Bull case and bear case

Bull case and bear case for Moderna

Where the evidence on Moderna stands: Holding on the latest evidence (Nov 17, 2026). Of its 5 thesis points, 5 holding.

Bull case: what the evidence supports

  • Moderna’s mRNA platform must produce commercially adopted products beyond the pandemic franchise, proving that shared mRNA design and manufacturing know-how can be reused across diseases rather than being a one-product success.

    sec.gov ↗

  • Seasonal respiratory vaccines must become a durable, priced commercial channel for Moderna, not merely a lower-volume replacement for pandemic purchasing.

    sec.gov ↗

  • Moderna has to make its R&D, manufacturing, and commercial infrastructure flexible enough for post-pandemic demand; otherwise the platform’s scientific optionality will be overwhelmed by fixed operating costs.

    sec.gov ↗

  • Management must pace pipeline investment so Moderna reaches value-inflecting approvals or partnerships before operating cash burn forces dilutive financing.

    sec.gov ↗

  • The platform advantage depends on retaining specialized mRNA, clinical, regulatory, and manufacturing talent that can reuse knowledge across programs; excessive cuts or attrition would slow pipeline conversion.

    sec.gov ↗

Bear case: what would count against it

  • Late-stage non-COVID mRNA programs fail efficacy or safety endpoints, showing the platform does not generalize.

    sec.gov ↗

  • CDC/ACIP or international advisory bodies narrow respiratory vaccine eligibility, reducing the recurring addressable market.

    sec.gov ↗

  • Large Phase 3 programs require sustained spending before commercial proof arrives.

    sec.gov ↗

Company research

Research on Moderna

Thesis-Break Engine

What has broken in Moderna’s thesis

Each break OptimistFi flagged on Moderna, dated — with what has historically followed the same kind of break across the market, not a forecast for Moderna.

peers+14%-15%-1%12 mo agonow+6 mo
Daily price, then where similar breaks led across the market: the typical -1% path vs comparable companies over six months, inside the middle-half range (+14% to -15%). A base rate, not a forecast.
  • Analyst downgradecondition set before this filing

    Across all companies, this kind of break has happened 12,641 times before. Those stocks trailed comparable companies by a median of 1% over the next six months, and 33% of them trailed it by 10 points or more.

  • CEO / officer changecondition set before this filing

    Across all companies, this kind of break has happened 16,849 times before. Those stocks trailed comparable companies by a median of 2% over the next six months, and 38% of them trailed it by 10 points or more.

  • Insider-selling clustercondition set before this filing

    Across all companies, this kind of break has happened 9,137 times before. Those stocks beat comparable companies by a median of 1% over the next six months, and 30% of them trailed it by 10 points or more.

Several kinds of break have stacked on Moderna at once. A cluster is a stronger read than any one signal alone.

How the Thesis-Break Engine works →Historical outcomes are measured against comparable companies after past breaks of the same kind, across all companies. Not a prediction.

MARKET + FINANCIAL SNAPSHOT

The numbers behind the thesis

Sourced from filings and market data

What Changed

  1. Mixed
    Entered a material definitive agreement.

    Moderna filed an SEC 8-K on 2026-11-16: Entered a material definitive agreement. It is a dated development that tests the current thesis.

  2. Mixed
    Director or principal officer change.

    Moderna filed an SEC 8-K on 2026-11-13: Director or principal officer change. It is a dated development that tests the current thesis.

  3. Mixed
    Reported results of operations (earnings release).

    Moderna filed an SEC 8-K on 2026-11-06: Reported results of operations (earnings release). It is a dated development that tests the current thesis.

Risks / falsifiers

What could break the thesis

  • Late-stage non-COVID mRNA programs fail efficacy or safety endpoints, showing the platform does not generalize.
  • CDC/ACIP or international advisory bodies narrow respiratory vaccine eligibility, reducing the recurring addressable market.
  • Large Phase 3 programs require sustained spending before commercial proof arrives.
  • Clinical failures force Moderna to fund additional large trials without partner support.
  • Key scientists, manufacturing leaders, or regulatory executives leave for BioNTech, large pharma, or other biotech competitors.

MRNA news

Loading headlines…

Financial statements

MRNA income statement

Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

MRNA: quick answers

When does Moderna (MRNA) report earnings next?
Moderna's next results are projected for February 12, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 6, 2026. Earnings calendar
What is MRNA's short interest?
As of October 30, 2026, 33.2M MRNA shares were sold short, 8.20% of its shares outstanding, up 1.8% from the count before. At the stock's average daily volume that is 1.8 days to cover. FINRA publishes the count twice a month. MRNA short interest history
Which well-known investors own MRNA?
1 of the 37 well-known funds tracked here reported MRNA shares in their latest 13F filing. By share of the fund's portfolio: Bridgewater Associates (Ray Dalio), 0.0%. Fund portfolios

MRNA in well-known investors’ portfolios

1 of 37 funds reported MRNA shares in their latest 13F filing. A 13F shows quarter-end positions and arrives up to 45 days later.

FundOf its portfolioValueChangeQuarter
Ray DalioBridgewater Associates0.00%$807K−84.6%Q2 2026

Every fund’s portfolio

ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.